# US 2019/0241615 A1 · Cyclic peptide inhibitors of hedgehog proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0241615 A1
- Document ID: US20190241615A1
- Status: Published application
- Kind: A1
- Application number: 16/311,598
- Filed: 2017-06-21
- Published: 2019-08-08
- Earliest claimed: 2016-06-22
- Inventors: Rudi Fasan; Andrew Owens
- Web page: https://patentgrep.com/patent/US20190241615A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/50: Cyclic peptides containing at least one abnormal peptide link
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Cyclic peptide compounds are provided that can bind to one or more homologs of Hedghehog signaling proteins and block their interaction with the Patched receptor. These compounds are useful for suppressing Hedgehog-dependent stimulation of the Hedgehog pathway in cells and in living organisms. Methods for using the cyclic peptide compounds, and compositions comprising them, for treatment of cancers and other diseases which are characterized by aberrant Hedgehog-dependent activation of the Hedgehog pathway and/or which can benefit from chemical suppression of Hedgehog-dependent signaling are also disclosed.

## Claims

### Claim 1

A cyclic peptide of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof:
wherein:
X1 is Thr, Asp, Phe, Glu, Asn, Gln, Ser, Tyr, substituted Phe, substituted Tyr, or substituted Trp;
X2 is Leu, His, Ser, Val, Trp, Ile, Phe, Tyr, Thr, Nval, Nleu, substituted Phe, substituted Tyr, or substituted Trp;
X3 is Asp, Ser, Lys, Thr, Val, Asn, Leu, Glu, Ile, Gln, Arg, Orn, Dab, Dap, Nleu, or Nval;
X4 is Asp, Trp, Gly, Ala, Pro, Tyr, Phe, Glu, Aib, substituted Phe, substituted Tyr, substituted Trp, or an amino acid of formula (IV)
wherein:
q is 0, 1, or 2; and Ar is a C5-C15 aryl group or a C5-C15 substituted aryl group;
X6 is Glu, Ser, Leu, Val, Trp, Gly, Ala, Arg, Tyr, Phe, Ile, Thr, Asp, Lys, Orn, Dab, Dap, substituted Phe, substituted Tyr, substituted Trp, Nval, or Nleu;
X7 is Glu, Ala, Lys, Gly, Tyr, Phe, Arg, Asp, Orn, Dab, Dap, substituted Phe, substituted Tyr, substituted Trp, Aib, 3,3,3-trifluoro-alanine, alpha,alpha-bis-trifluoromethyl-glycine, or 2-cyclopropylglycine;
X8 is Met, Nleu, Gly, or Pro;
X9 is Asp, Glu, Cys, His, or an amino acid residue of formula (III)
wherein:
q is 0, 1, or 2; and Z3 is selected from the group consisting of —CONHOH, —N(OH)COCH3, —CONHOCH3, —ONHCOCH3, —P(=O)(OH)2, —P(═O)H(OH), —SO3H, —SO2NH2, —NHSO2CH3, —CONHSO2CH3, —NHCONHSO2CH3, imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, —CH(OH)CF3, —C(OH)2CF3, thiazolidine-2,4-dione, oxazolidine-2,4-dione, 1,2,4-oxadiazol-5(4H)-one, 1,2,4-thiadiazol-5(4H)-one, 3H-1,2,3,5-oxathiadiazole 2-oxide, 1,2,4-oxadiazole-5(4H)-thione, isoxazol-3-ol, isothiazol-3-ol, pyrrolidine-2,4-dione, furan-2,4(3H,5H)-dione, 3-hydroxycyclopent-2-enone, 3-hydroxycyclobut-3-ene-1,2-dione, and 2,6-difluorophenol;
X10 is Gly, Met, D-Met, Nleu, D-Nleu, Thr, D-Thr, Ser, D-Ser, or —N(R9)CH2C(O)—, wherein R9 is a C1-C15 aliphatic, C1-C15 substituted aliphatic, C5-C15 aryl, C5-C15 substituted aryl, C6-C15 alkylaryl, or C6-C15 substituted alkylaryl group;
X12 is Ser, Thr, Met, Leu, Ile, Val, Nleu, or Nval;
X13 is Asp, Glu, or absent;
X5 is Met, Gly, or Nleu;
R1 is hydrogen, an acetyl group, a label molecule, or a R13CO— group, wherein R13 is C5-C15 alkanoic acid or C5-C15 alkenoic acid;
R2 and R3 are, independently, a hydrogen or an alkyl group comprising between one and three carbon atoms;
R4 is hydrogen, or a linear or branched alkyl group comprising between one and eight carbon atoms;
R12 is —OH or NH2;
L1 is a linker unit, such that the linear dimension between the Cα carbon atoms connected by the linker unit is between about 6 and 15 Angstrom units; and
L2 is a linker unit, such that the linear dimension between the Cα carbon atoms connected by the linker unit is between about 5 and 12 Angstrom units;
and wherein the cyclic peptide is able to bind at least one homolog of a Hedgehog protein.

### Claim 2

A cyclic peptide of Formula (I), or a pharmaceutically acceptable salt thereof:
wherein:
X1 is Thr, Asp, Phe, Glu, Asn, Gln, Ser, or Tyr;
X2 is Leu, His, Ser, Val, Trp, Ile, Phe, Tyr, or Thr;
X3 is Asp, Ser, Lys, Thr, Val, Asn, Leu, Glu, Ile, Gln, Gly, Pro, Ala, Trp or Arg;
X4 is Asp, Trp, Gly, Ala, Pro, Tyr, Phe, or Glu;
X6 is Glu, Ser, Leu, Val, Trp, Gly, Ala, Arg, Tyr, Phe, Ile, Thr, Asp, or Lys;
X7 is Glu, Ala, Lys, Gly, Tyr, Phe, Arg, or Asp;
X8 is Met, Nleu, Gly, or Pro;
X9 is Asp or Glu;
X10 is Gly, Met, Nleu, Thr, or Ser;
X12 is Ser, Thr, Met, Leu, Ile, or Val;
X13 is Asp, Glu, or absent;
R1 is hydrogen, an acetyl group, or an acyl group;
R2 and R3 are, independently, a hydrogen or an alkyl group comprising between one and three carbon atoms;
R4 is hydrogen, or a linear or branched alkyl group comprising between one and eight carbon atoms;
R12 is —OH or NH2; and
L1 is a linker unit, such that the linear dimension between the Ca carbon atoms connected by the linker unit is between about 6 and 15 Angstrom units.

### Claim 3 (depends on 2)

The cyclic peptide of claim 2, wherein X1 is Thr; X2 is Leu, His, Ser, Val, or Trp; X3 is Asp, or Ser; X4 is Asp, Trp, or Gly; X6 is Glu, Ser, Leu, Val, Trp, Gly, Ala, Arg, Tyr, or Phe; X7 is Glu, Ala, Lys, or Gly; X8 is Met; X9 is Asp; X10 is Gly, or Met; X12 is Ser, or Thr; X13 is Asp.

### Claim 4

A cyclic peptide of Formula (II), or a pharmaceutically acceptable salt thereof:
wherein:
X1 is Thr, Asp, Phe, Glu, Asn, Gln, Ser, or Tyr;
X2 is Leu, His, Ser, Val, Trp, Ile, Phe, Tyr, or Thr;
X3 is Asp, Ser, Lys, Thr, Val, Asn, Leu, Glu, Ile, Gln, or Arg;
X4 is Asp, Trp, Gly, Ala, Pro, Tyr, Phe, or Glu;
X5 is Met or Gly;
X6 is Glu, Ser, Leu, Val, Trp, Gly, Ala, Arg, Tyr, Phe, Ile, Thr, Asp, or Lys;
X7 is Glu, Ala, Lys, Gly, Tyr, Phe, Arg, or Asp;
X9 is Asp or Glu;
X10 is Gly, Met, Nleu, Thr, or Ser;
X12 is Ser, Thr, Met, Leu, Ile, or Val;
X13 is Asp, Glu, or absent;
R1 is hydrogen, an acetyl group, or an acyl group;
R2 and R3 are, independently, a hydrogen or an alkyl group comprising between one and three carbon atoms;
R4 is hydrogen or an alkyl group comprising between one and eight carbon atoms;
R12 is —OH or NH2; and
L2 is a linker unit, such that the linear dimension between the Cα carbon atoms connected by the linker unit is between about 5 and 12 Angstrom units.

### Claim 5 (depends on 4)

The cyclic peptide of claim 4, wherein X1 is Thr; X2 is Leu; X3 is Asp; X4 is Asp; X5 is Met; X6 is Glu; X7 is Glu; X8 is Met; X9 is Asp; X10 is Gly; X12 is Ser, Leu, or Val; X13 is Asp.

### Claim 6 (depends on 1)

The cyclic peptide of claim 1, wherein L1 is —R9—S—R10— or —R10—S—R9—, wherein R9 is an alkylaryl or a substituted alkylaryl group comprising between 5 and 20 carbon atoms, and R10 is an alkyl or a substituted alkyl group comprising between 1 and 10 carbon atoms.

### Claim 7 (depends on 6)

The cyclic peptide of claim 6, wherein L1 is
wherein n is an integer number comprised between 1 and 6; m is an integer number comprised between 1 and 3; and R5 and R6 are, independently, a hydrogen atom or a methyl group.

### Claim 8 (depends on 1)

The cyclic peptide of claim 1, wherein L1 is —(CH2)n—ZHCH2)p—, wherein Z1 is —S—, —S—S—, —NHCO—, —CONH—, —CH═CH—, —(CH2)2—, —CH≡CH—, or a triazole group, and n and p are, independently, an integer number between 1 and 6.

### Claim 9 (depends on 1)

The cyclic peptide of claim 1, wherein L1 is —C(R5R6)m—S—Z2—S—C(R7R8)o, wherein Z2 is selected from the group consisting of a C1-C10 alkyl, C1-C10 substituted alkyl, C2-C10 alkenyl, C2-C10 substituted alkenyl, C6-C12 aryl, C6-C12 substituted aryl, C8-C14 alkylaryl, C8-C14 substituted alkylaryl group, —CH2COCH2—, and —CH2COCOCH2—; m and o are, independently, an integer number comprised between 1 and 3; R5, R6, R7, and R8 are, independently, a hydrogen atom or a methyl group.

### Claim 10 (depends on 1)

The cyclic peptide of claim 1, wherein L2 is —R9—S—R10— or —R10—S—R9—, wherein R9 is an alkylaryl or a substituted alkylaryl group comprising between 5 and 20 carbon atoms, and R10 is an alkyl or a substituted alkyl group comprising between 1 and 10 carbon atoms.

### Claim 11 (depends on 10)

The cyclic peptide of claim 10, wherein L2 is
wherein n is an integer number comprised between 1 and 6; m is an integer number comprised between 1 and 3; and R5 and R6 are, independently, a hydrogen atom or a methyl group.

### Claim 12 (depends on 1)

The cyclic peptide of claim 1, wherein L2 is —(CH2)n—Z1—(CH2)p—, wherein Z1 is —S—, —S—S—, —NHCO—, —CONH—, —CH═CH—, —(CH2)2—, —CH≡CH—, or a triazole group, and n and p are, independently, an integer number between 1 and 6.

### Claim 13 (depends on 1)

The cyclic peptide of claim 1, wherein L2 is —C(R5R6)m—S—Z2—S—C(R7R8)o, wherein Z2 is selected from the group consisting of a C1-C10 alkyl, C1-C10 substituted alkyl, C2-C10 alkenyl, C2-C10 substituted alkenyl, C6-C12 aryl, C6-C12 substituted aryl, C8-C14 alkylaryl, C8-C14 substituted alkylaryl group, —CH2COCH2—, and —CH2COCOCH2—; m and o are, independently, an integer number comprised between 1 and 3; R5, R6, R7, and R8 are, independently, a hydrogen atom or a methyl group.

### Claim 14 (depends on 1, 2)

The cyclic peptide of claim 1, 2 or 1, wherein at least one among residues X1, X2, X3, X4, X5, X6, and X7 is an alpha,alpha-disubstituted amino acid carrying an alpha-methyl group.

### Claim 15 (depends on 1)

The cyclic peptide of claim 1, wherein at least one of residue X1, X2, X10, X11, X12, and X13 is an N-methylated amino acid.

### Claim 16 (depends on 1)

The cyclic peptide of claim 1, wherein the peptide comprises a warhead group.

### Claim 17 (depends on 16)

The cyclic peptide of claim 16, wherein the warhead group is —SO2F, —Ar2—SO2F, —(CH2)nSO2F, —Ar2—NCS, —NHSO2CH═CH2, or —(CH2)rCH2Br, wherein Ar2 is a C5-C10 aryl or a C5-C10 substituted aryl group; n is an integral number between 1 and 6; r is an integral number between 1 and 10.

### Claim 18 (depends on 1)

The cyclic peptide of claim 1, wherein L1 is —CH2SSCH2—, —CH2SCH2SCH2—, —CH2S(CH2)2SCH2—, —CH2S(CH2)3SCH2—, —CH2S(CH2)4SCH2—, —CH2S(CH2)5SCH2—, —CH2SCH2CH═CHCH2SCH2CH2—,

### Claim 19 (depends on 1)

The cyclic peptide of claim 1, wherein the peptide is one selected from a peptide set forth in Tables 1, 2, 3 or 4.

### Claim 20 (depends on 1)

The cyclic peptide of claim 1, wherein the peptide comprises a label molecule selected from an affinity label molecule, a photoaffinity label, a dye, a chromophore, a fluorescent molecule, a phosphorescent molecule, a chemiluminescent molecule, an energy transfer agent, a photocrosslinker molecule, a redox-active molecule, an isotopic label molecule, a spin label molecule, a radioactive moiety, a contrast agent molecule, a MRI contrast agent, an isotopically labeled molecule, a PET agent, an electron dense group, a magnetic group, a cofactor, a biotin, a biotin analogue or a combination thereof.

### Claim at position 21

21-25. (canceled)
